User:Alexander Cherkasky

I am biologist with Masters degree and inventor. My inventions include new anticancer and anti-inflammatory treatments, novel multiparallel diagnostic systems, novel fast genome sequencing systems, new lubricants and new materials. I have 34 publications in patent literature including German patents, US patent applications, international PCT patent applications and German Patent applications. I got 7 German patents and have also 4 published US Patent Applications. I invent since early youth and as I was student at Goethe-Gymnasium in Dusseldorf, I presented my inventions of Anti-Alzheimer's disease therapy and anticancer therapy on scientific youth competitions "Youth researches" (Yugend forscht) in the years 1999 and 2000. In 1999 I have presented my invention of biomolecules that specifically bind and cleave pathogenic proteins especially so-called beta-amyloid plaques. In 2000, I have presented fusion proteins that selectively inhibit division of target cancer cells. It evoked interest of journalists. About me and inventions of mine reported known newspapers and magazines including Stern(The Star), Rheinische Post (The Rhein Post), Westdeutsche Zeitung (Westgerman Newspaper) and other media. I am also the inventor of ordered DNA winding around the bobbins (my German Patent DE 19929530). In the year 2003, I was awarded the Bronze Medal "For Outstanding Achievements" and the Honorary Certificate of the International Exhibition and Competition of Inventors "Ideas-Inventions-New Products" IENA 2003 in Nuremberg. IENA is the largest international inventors exhibition and competition in Germany already over 60 years. My name was also placed on the Young Inventors International Hall of Fame. I was only one inventor from Germany whose name was placed on this Hall of Fame. My invention of novel lubricants was selected and published by the largest Chinese data provider Wanfang Data, which is affiliated with the Chinese Ministry of Science and Technology and customers of Wanfang include Governments, Library of Congress, Yale and Oxford Universities. Wanfang scanned patent literature worldwide, and recognized in this my lubricant invention a very big commercial potential.

Paradoxally, certain of my inventions were confirmed experimentally with success and were published both in scientific and US patent literature but although my name was not mentioned, my priority and my authorship are documented clearly. The examples include the following:

1. My invention of a medicine comprising protease region for cleavage, combined with the beta-amyloid region for selective recognition and binding in order to cleave specifically the beta-amyloid plaques by Alzheimer’s disease and other amyloid-associated diseases was presented by myself during youth scientific competition “Youth researches” (“Jugend forscht”) in1999 and was highlighted in the most popular magazine in Germany Stern (The Star) (March 25, 1999). In that article my invention was described and named revolution. My patent application DE19822406 for this invention, especially for protease fusion proteins specifically for cleaving amyloid proteins in order to treat amyloid diseases causally, was filed with the German Patent and Trademark Office on May 19,1998 and was published on November 25, 1999. The group of Roger Nitsch, Johannes Pohlner, Axel Wollmer and Hasan Mohajeri which are employed at Evotec NeuroSciences GmbH in Germany and at the University of Zurich, tried to get patents for “Methods and compounds for treating brain amyloidosis”, which is invention of mine. They filed the European patent application EP00120449.4 on September 19, 2000 and then international patent application WO0225279, PCT/EP01/10816, as well as two US patent applications US 20040038302 (filed on July 29, 2003 in the US) and US20060142194 (filed on November 16, 2005). Thus I have the priority. So in addition to the fact of my priority and authorship of my invention, it is well documented and confirmed that my inventions deserve to be implemented commercially. The following are the links to my German patent application DE 19822406 and to two US patent applications US20040038302 and US 20060142194.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=19991125&CC=DE&NR=19822406A1&KC=A1

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040038302%22.PGNR.&OS=DN/20040038302&RS=DN/20040038302

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060142194%22.PGNR.&OS=DN/20060142194&RS=DN/20060142194

2. My invention of socalled Fc-Autoantigen fusion proteins for causal treatment of autoimmune diseases such as multiple sclerosis, was described in my published German patent application DE10160248, filed on December 07,2001 and published on June 26, 2003. The German company Micromet AG, with quarters in Munich and Bethesda, MD, USA, filed later (February 13, 2002) the European patent application EP02003332, and international patent application PCT/EP03/01389, published as WO03/068822 on August 21,2003. Micromet Inc. is on the stock exchange NASDAQ and its ticker symbol is MITI. The examiner with the United States Patent and Trademark Office (USPTO) Prema Mertz missed my published German patent application and granted to Micromet the US Patent 7323440 on January 29, 2008. There are surprisingly and obviously many similarities in claims and description and examples between my earlier patent application and their patent so that the patent to them was issued by an error of the examiner. Below are the links to my patent application DE 10160248 and the US patent 7322440.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20030626&CC=DE&NR=10160248A1&KC=A1

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7323440.PN.&OS=PN/7323440&RS=PN/7323440

3. A Japanese group of Kyohei Terao, Masao Washizu and Hidehiro Oana experimentally confirmed my inventions for sequencing and manipulation of giant DNA sequences described in two my German patents DE19929530B4 and DE19937512B4 filed in 1999 and published in 2001. In my German patent DE19929530B4 is described my invention of ordered winding DNA around the bobbins and this work was carried out by the above-mentioned Japanese group and claimed as sensation. Their paper “On-site manipulation of single chromosomal DNA molecules by using optically driven mictostructures” was published on June 23, 2008 in the journal Lab on a Chip of the Royal Society of Chemistry in the UK. Their work was highlighted in Chemical Science and in New Scientist. Thereby my German patent DE 19937512 was mentioned by American inventor Rouvain Bension in his US patent 7163658. There are links to the patents DE 199 29530, DE 199 37512 and US 7163658 as well as to certain related articles.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20010104&CC=DE&NR=19929530A1&KC=A1

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20010215&CC=DE&NR=19937512A1&KC=A1

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7163658.PN.&OS=PN/7163658&RS=PN/7163658

http://www.rsc.org/Publishing/Journals/LC/article.asp?doi=b803753a

http://www.rsc.org/Publishing/ChemScience/Volume/2008/07/Miniaturised_sewing_machines.asp

http://www.internetchemie.info/news/2008/jul08/dna-sewing-machine.html

4. The Nobel Laureate Joshua Lederberg tried to get priority for the invention for which I have well documented priority. This invention concerns genetically engineered medicine carriers especially bacteriophage-antibody and bacteriophage-receptor complexes against bacterial diseases and cancer. His US Patent Application 20040033584 was filed as a PCT international application on December 21, 2000, it means later than my earlier German patent application DE19818938A1, filed on April 28, 1998 and published in November 4, 1999. Lederberg was a famous scientist and is considered as the father of molecular biotechnology and his experiments were basis for the experiments of Stanley N. Cohen and Herbert Boyer, inventors of recombinant DNA technology, of genetic engineering. Interestingly, Lederberg’s last invention was my first invention. Please see below the links to DE 19818938 and US 20040033584.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=19991104&CC=DE&NR=19818938A1&KC=A1

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040033584%22.PGNR.&OS=DN/20040033584&RS=DN/20040033584

These facts are also confirmations for sponsors, investors and potential business partners that my inventions work and are worthy to be implemented commercially.

In conclusion, that the invention implementation process is the key process for economic growth and development I propose the new economic model based upon the renewal of patent law and patent system as well as the creation and establishing of the invention implementation system in order to motivate inventors and more efficiently implement inventions of new therapies and technologies:

1. Condition-Dependent or Condition-Responsive Patents (CoDe Patents or CoRe Patents)

The patent protection will be switched in dependence of or in response to defined conditions (Condition-Responsive Protection Switching). Preferably three levels of protection (Condition Dependent or Condition-Responsive Protection Levels) may be distinguished:

1.1. If an invention does not bring profits to inventor or company (no profit condition) and nobody tried to obtain license, the invention should remain protected both free-of-charge and unlimited in time.

1.2. If invention will be entered to market and begins to bring profits, than patent costs may arise and time of protection may be limited to 20 years from entry to market. Thus, my Cherkasky Theory of Living or Switching Patent System is conform with Anti-Trust Law.

1.3. As soon as an invention pays off initial investments and continues to bring profits to inventor or company, government can be directly shared in these profits in addition to taxes from these profits as compensation for free of charge protection in level 1.1. Switch from 1.1 to 1.2 may be reversible in certain exceptions, but switch from 1.2 to 1.3 is irreversible. The futuristic legislative act can be named Condition-Responsive Patent Act. Thus, the patent system will be made living. The Switching Patent System or Condition-Dependent Switching Patent System issuing Condition-Dependent Patents can be established on the basis of existing patent system. It can be governmentally funded and refunded by incomes from increasing number of successful implementations and commercialisation of more new inventions. The legislative act for establishing such system or for improvement of current patent system can be named Switching Patent System Act or Switching Patent Act.

2. Free of Charge Protection of Inventions

Each inventor should have legal possibility to protect his invention free of charge but for share of government.

3. Expansion of Patent Office Network

For dynamic consideration of increasingly number of filed patent applications, the Patent Office Network can be expanded and contain regional and local offices.

4. Publication after Filing

Patent applications should be published directly after filing and than searched and examined. After-filing-publications will increase transparency and allow secure searches and reduction of investment risks.

5. Invention Implementation Office or Invention Implementation System

Billions are invested in seeking new solutions for healing diseases such as cancer. The futuristic Invention Implementation Act can build the basis for establishing the Invention Implementation System and allow to solve problems dynamically and to maximize innovation, because inventions as problem solutions must be evaluated and implemented independently from status of inventor and high values of inventions may not be reduced or destroyed. I propose to establish Laboratories for Implementation of Inventions especially of Biotechnological Inventions in order to openly constructively evaluate and implement inventions independently from status of inventor. The inventions can be selected in current idea competition. Experimental scientists working for implementation must be rewarded additionally for successful implementations. Thus, more inventions will be implemented, more problems will be dynamically solved and after successful proofs, investment risks will be reduced, managers can be found easier, more new companies can be established with share of government, investors and inventors. Thus, more people will get more new causal therapies.

6. Office for Promotion of Inventors and Inventions

I propose to establish the Office for Promotion of Inventors and Inventions in order to evaluate constructively and scale inventions according to their potential, find producers and managers for joint ventures with inventors and find companies interested in obtaining licences as well as organize significantly rewarded competitions in order to find and promote solutions of problems.

7. Patent Exchange and New Patent Market

Strong patent protection for high values will open new possibilities not only for inventors, but also for investors and for new managers, wishing to make new companies and seeking for suitable ideas.

Parties involved will profit from the suggestions: Government will obtain new sources of income and investors will get more investment options and reduction of risk. Inventors and companies will be more motivated to create in a secure legal medium. More new cures will be created and entered to market as well as more new careers will be possible.